<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260802070494N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of honeysol and silymarin in oral mucositis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of silymarin and honisol mouthwashes with standard care in preventing radiotherapy-induced oral mucositis: a randomizedclinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>63</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92305</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be allocated into the three study groups using a block-balanced randomization method with random blocks of three. The randomization sequence will be generated using block randomization software, Blinding description: The randomization sequence and allocation envelopes were prepared and maintained by a person outside the clinical evaluation team to reduce the risk of allocation bias. The study drugs were identical in appearance. The treatment team and the evaluators of mucositis severity were blinded to the randomization sequence.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral mucositis in patients with head and neck radiotherapy.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Patients used 5 cc of 0.9% normal saline as a mouthwash three times a day for 5 weeks, and then spit it out.The solution is stored in dark containers. Intervention 2: Intervention group: To prepare the silymarin mouthwash, 140 mg silymarin tablets (produced by Goldaru Pharmaceutical Company) will be used. Each tablet will be dissolved in 100 ml of sterile normal saline to obtain a uniform solution. To ensure complete dissolution, the tablet will first be crushed and then dissolved under gentle agitation. The prepared solution must be fresh and will be prepared on a daily basis. The final concentration of silymarin will be 140 mg/100 ml (1.4 mg/ml). After preparation, the solution will be stored in a dark, sealed container. Patients will be instructed to hold 10 ml of the solution in their mouth, gargle for 1 minute, and then expectorate it, three times a day. The recommended duration of 1 minute for using the silymarin mouthwash is based on standard protocols in pharmacological studies. This duration allows sufficient time for effective contact between the active ingredient and the oral mucosa to achieve maximum therapeutic effect. Previous studies on therapeutic mouthwashes have also frequently recommended 30-to-60-second intervals for optimal efficacy. Intervention 3: Intervention group: The Honey-Sol syrup, containing 20% honey and 5% turnip extract in a 120 ml volume, will be used as a mouthwash. The syrup will be mixed with sterile distilled water at a 1:2 (v/v) ratio. The solution will be stored in light-resistant (dark) containers. Patients will rinse their mouths with 10 ml of the solution three times daily and then expectorate it.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information is suitable dor publication

When:
Access begina at the start of the year 1407 and remains available for six month

To whom:
It is exclusively for those employed at academic institution

Conditions:
There is no limitation

Where to obtain:
09354186303 is the researcer contact .hosseinghezel82@gmail.com is the researcher email address

How to obtain:
Inquiries directed to the researher will be answered whith in 24 hours including responses to emails

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Ghezelsefloi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Numver 1470, North Kargar street, North Amirabad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439957181</zip>
        <telephone>+98 911 510 6303</telephone>
        <email>hosseinghezel82@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Ghezelsefloo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>, Number 1470, Kouy University of Medical Sciences Dormitory،Kargar Shomali street, Amir abad shomali</address>
        <city>تهران</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۹۹۵۷۱۸۱</zip>
        <telephone>+98 935 418 6303</telephone>
        <email>hosseinghezel82@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing radiotherapy for head and neck cancer
The radiotherapy regimen for patients consists of 30 sessions with a total dose of 75 Gray</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with systemic diseases that cause oral ulceration and mucositis
pregnant women;
patients undergoing chemoradiotherapy.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Oral mucositis (ulcerative), unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Patients used 5 cc of 0.9% normal saline as a mouthwash three times a day for 5 weeks, and then spit it out.The solution is stored in dark containers</i_keyword>
      <i_keyword>Intervention group: To prepare the silymarin mouthwash, 140 mg silymarin tablets (produced by Goldaru Pharmaceutical Company) will be used. Each tablet will be dissolved in 100 ml of sterile normal saline to obtain a uniform solution. To ensure complete dissolution, the tablet will first be crushed and then dissolved under gentle agitation. The prepared solution must be fresh and will be prepared on a daily basis. The final concentration of silymarin will be 140 mg/100 ml (1.4 mg/ml). After preparation, the solution will be stored in a dark, sealed container. Patients will be instructed to hold 10 ml of the solution in their mouth, gargle for 1 minute, and then expectorate it, three times a day. The recommended duration of 1 minute for using the silymarin mouthwash is based on standard protocols in pharmacological studies. This duration allows sufficient time for effective contact between the active ingredient and the oral mucosa to achieve maximum therapeutic effect. Previous studies on therapeutic mouthwashes have also frequently recommended 30-to-60-second intervals for optimal efficacy.</i_keyword>
      <i_keyword>Intervention group: The Honey-Sol syrup, containing 20% honey and 5% turnip extract in a 120 ml volume, will be used as a mouthwash. The syrup will be mixed with sterile distilled water at a 1:2 (v/v) ratio. The solution will be stored in light-resistant (dark) containers. Patients will rinse their mouths with 10 ml of the solution three times daily and then expectorate it.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sevieeity of oral mucusitis. Timepoint: Before starting the study, 3 weeks later, 5 weeks later(end of the study). Method of measurement: Clinical examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-08</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran university dormitories , North Kargar ,North Amirabad Town , Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
